Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Years Ended · | |||||||
| · · December 31, · | |||||||
| · · 2025 · · 2024 · | |||||||
| · · · · · | |||||||
| OPERATING EXPENSES · · · · | |||||||
| Research and Development | | $1,834,506 | | $5,403,836 | | ||
| General and Administrative | | 6,257,477 | | 8,719,391 | | ||
| | | | | | | | |
| TOTAL OPERATING EXPENSES | | 8,091,983 | | 14,123,227 | | ||
| | | | | | | | |
| OPERATING LOSS | | | (8,091,983) | | | (14,123,227) | |
| | | | | | | | |
| OTHER INCOME | | | | | | | |
| Interest Income | | | 125,445 | | | 20,124 | |
| | | | | | | | |
| NET LOSS | | $(7,966,538) | | $(14,103,103) | | ||
| | | | | | | | |
| LOSS PER SHARE | | | | | | ||
| Basic and diluted net loss per common share | | $(5.32) | | $(17.45) | | ||
| | | | | | | | |
| Weighted average common shares outstanding, basic and diluted | | 1,498,793 | | 808,168 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.